ERBB2 and breast carcinoma: Based on the aforementioned protein kinase inhibitory activity of thiazole and pyrazoline nuclei, especially on EGFR and HER2, a strategy of hybridizing these two luminous moieties was designed to synthesize dual EGFR/HER2 hybrid modulators/inhibitors targeting breast cancer [51].